Eikon Therapeutics Inc. (EIKN)
NASDAQ: EIKNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EIKN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $256.84M
- EPS (TTM)
- -$7.86
- Dividend yield
- None
- 52-week range
- 4.72 – 17.40
- Day range
- 4.74 – 5.19
- Volume / Avg
- 691.44K / 560.40K
- Beta
- —
- Shares outstanding
- 54.19M
52-week range
EIKN stock today
Shares of Eikon Therapeutics (EIKN) finished lower on Nov 20 at $4.74, a drop of 0.42% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 72.8% below their 52-week high of $17.40, set on Feb 5, 2026 and 0.4% above the 52-week low of $4.72, near the bottom of the past year's range. Eikon Therapeutics has posted a net loss over the last twelve months (EPS of -$7.86), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Eikon Therapeutics
Company profileEikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Roger M. Perlmutter M.D., Ph.D.
- Headquarters
- Millbrae, CA
- Employees
- 384
- IPO year
- 2026
- Website
- eikontx.com
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$24.00+406.33%
- Strong buy 2
- Buy 4
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.59 vs $-1.74
- Surprise
- +8.62%
EIKN news
All EIKN news- Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate CancerGlobeNewswire
- Eikon Therapeutics, Inc. Loss At -$86.112 Mln In Q3NasdaqEIKN, LEN.B
- Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswire
- Eikon Therapeutics to Participate in Multiple Investor Conferences in NovemberGlobeNewswire
- Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology CongressGlobeNewswire
- Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology CongressGlobeNewswire
- Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology CongressGlobeNewswire
- HC Wainwright & Co. Initiates Coverage of Eikon Therapeutics with Buy RatingNasdaq
Eikon Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs EIKN |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs EIKN |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs EIKN |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs EIKN |
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs EIKN |
| AGENAgenus Inc. | 5.97 | -2.77% | $270.12M | vs EIKN |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs EIKN |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs EIKN |
Indexes, lists and sector
Eikon Therapeutics stock FAQ
What is Eikon Therapeutics's stock price today?
EIKN last traded at $4.74 as of Nov 20, 4:00 PM EST, down 0.42% on the day. Prices are delayed at least 15 minutes.
Who is Eikon Therapeutics's CEO?
Dr. Roger M. Perlmutter M.D., Ph.D. is the chief executive officer of Eikon Therapeutics Inc., which has about 384 employees.
What is the EIKN 52-week high?
The 52-week high for EIKN is $17.40 and the 52-week low is $4.72. The stock is currently 72.8% below its high.